Journal
CONTRACEPTION
Volume 97, Issue 4, Pages 354-356Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.contraception.2017.12.007
Keywords
Contraceptive use; Medroxyprogesterone acetate (MPA); Levonorgestrel (LNG); Misreporting; Discordance
Categories
Funding
- U.S. Centers for Disease Control and Prevention (CDC) [U48DP001944, 200-2015-M-63021]
- National Institutes of Health (NIH) [1K01-TW009657-01, P30-AI50410]
- Bill & Melinda Gates Foundation [OPP1090837]
- U.S. Agency for International Development [AID-OAA-A-15-00045]
- Bill and Melinda Gates Foundation [OPP1090837] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Objective: The objective was to assess the extent of concordance between self-reported contraceptive use and the presence of contraceptive progestins in serum. Study design: We evaluated self-reported contraceptive use by using radioimmunoassay to examine baseline serum levels of medroxyprogesterone acetate (MPA) and levonorgestrel (LNG) among 97 Malawian women enrolling in a contraceptive trial. Results: Twelve percent (12/97) of study participants who reported no hormonal contraceptive use in the previous 6 months had either MPA or LNG detected in their serum. Conclusions: The observed discordance between self-report and detection of exogenous hormones in serum indicates that caution is warranted when drawing conclusions based on self-reported contraceptive use. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available